STAT+: Most-favored nations policy makes drugmakers rethink launches abroad

Biogen under investigation, lawsuits over off-label GLP-1 promotion, and more biotech news Adobe Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Thanksgiving is approaching and I’ve yet to make an all-butter pie crust that doesn’t shrink. Any tips or suggestions appreciated! A former Eli Lilly sales rep filed a lawsuit alleging that she was fired after complaining that the company promoted its Mounjaro diabetes drug as a weight loss treatment before receiving regulatory approval to do so. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.